Maridebart Cafraglutide: A Physician’s Read on a Monthly GLP-1 Antibody-Peptide Conjugate
A GLP-1 agonist carried by a GIP receptor blocking antibody, dosed every 4 to 8 weeks. A short physician’s read on the design, the data and the open questions.
Frailty Should Not Preclude Semaglutide? My Read of the SELECT Frailty Analysis
A post hoc analysis of SELECT applied a 31-item frailty index to 17,604 adults. The heart benefit looked consistent across frailty levels. Here is what it shows, what it can’t, and how I would pair it with strength and protein.